U.S. flagAn official website of the United States government
                    Here's how you know **Official websites use .gov**
                            
                            A **.gov** website belongs to an official government organization in the United States.
 **Secure .gov websites use HTTPS**
                            
                            A **lock** (                            
                              A locked padlock                                                      
                            
                            ) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.


Menu Agricultural Research Service
						
                    U.S. DEPARTMENT OF AGRICULTURE
 Obesity and Metabolism Research: Davis, CA
 close



    Research

                    Research Projects
                                    Publications
                                    Collaborations
                                    News
                People

                    Staff Listing
                                    Careers


        


                    Laboratories
                        Bennett Group
                                    Huang Group
                                    Keim Group
                                    Laugero Group
                                    Newman GroupSearch small
                    Search
            
            ARS Home
                                About ARS
                                Contact Us




ARS Home Pacific West Area Davis, California Western Human Nutrition Research Center Obesity and Metabolism Research Research Publications at this Location





- ARS National Programs
- Search for a scientific manuscript
- Search for a research project
- ARS Software
- Programs and Projects
- Collaborations
- Subjects of Investigation
- Publications

Title:   Author  item
                                            Laugero, Kevinitem
                                            STONEHOUSE, A - AMYLIN PHARMACEUTICALSitem
                                            GUSS, S - AMYLIN PHARMACEUTICALSitem
                                            LANDRY, C - AMYLIN PHARMACEUTICALSitem
                                            PARKES, D - AMYLIN PHARMACEUTICALS
  Submitted to: Metabolic Syndrome and Disorders
                                    Publication Type: Peer Reviewed Journal
                                    Publication Acceptance Date: 1/16/2009
                                    Publication  Date: 8/1/2009
                                    Citation: Laugero, K.D., Stonehouse, A.H., Guss, S., Landry, C.V., Parkes, D.G. 2009. EXENATIDE IMPROVES HYPERTENSION IN A RAT MODEL OF THE METABOLIC SYNDROME. Metabolic Syndrome and Disorders. 7(4):327-34, 2009.Interpretive Summary: Exenatide is a peptide that helps with the regulation of glucose metabolism. The actions of this peptide are also associated with weight reduction. Our findings are the first demonstration of a durable anti-hypertensive effect of exenatide in a rat model of the metabolic syndrome.
                                Technical Abstract: Exenatide is a peptide incretin mimetic that has glucoregulatory actions associated with weight reduction. Previous reports demonstrated acute increases in blood pressure after systemic or intracerebroventricular administration of exenatide or glucagon-like peptide-1 (GLP-1) in rats. However, there are no reported studies testing the chronic effects of these peptides on arterial pressure in the rat. Thus, we examined the response to peripheral exenatide using telemetry in conscious, unrestrained rats under normotensive conditions and in a model of hypertension/metabolic syndrome induced by corticosterone. Rats were implanted with either corticosterone or wax (control) pellets (1 ug/kg/d) or vehicle for 7 days. The 21-day corticosterone treatment produced hypertriglyceridemia, visceral fat deposition, hyperglycemia, insulin resistance, and an elevation of mean arterial blood pressure (MAP) by 14 ± 1 mm Hg. Exenatide significantly reversed corticosterone-induced increases in blood presure and this normalization occurred independently from change in body weight. Additionally, exenatide reduced MAP by 5 ± 3 mm Hg in normotensive control rats. These results are the first demonstration of a durable anti-hypertensive effect of exenatide in a glucocorticoid-induced model of the metabolic syndrome.


Return to top


Connect with ARS Sign up


ARS Home
                            USDA.gov
                            Plain Writing
                            Policies & Links
                            Civil Rights Statements
                            FOIA
                            Accessibility Statement
                            Privacy Policy
                            Non-Discrimination Statement
                            Quality of Information
                            USA.gov
                            WhiteHouse.gov